Blinatumomab has demonstrated efficacy in B-cell acute lymphoblastic leukemia(B-ALL),achieving a measurable residual disease(MRD)negativity rate of 78%(1).Its addition to consolidation chemotherapy or administration p...Blinatumomab has demonstrated efficacy in B-cell acute lymphoblastic leukemia(B-ALL),achieving a measurable residual disease(MRD)negativity rate of 78%(1).Its addition to consolidation chemotherapy or administration prior to allogeneic hematopoietic stem cell transplantation(allo-HSCT)has been shown to significantly improve overall survival(OS)and relapse-free survival(RFS)in adult B-ALL patients(2,3).展开更多
Central nervous system(CNS)relapse in children with acute lymphoblastic leukemia(ALL)remains an obstacle for long-term survival.Though chimeric antigen receptor T-cells(CAR-T)or hematopoietic stem cells transplant(HSC...Central nervous system(CNS)relapse in children with acute lymphoblastic leukemia(ALL)remains an obstacle for long-term survival.Though chimeric antigen receptor T-cells(CAR-T)or hematopoietic stem cells transplant(HSCT)therapy was successfully developed,failure occasionally occurs.In this study,a child with TCF3-PBX1 B-ALL who relapsed a second time after CAR-T therapy followed by allo-HSCT was treated with blinatumomab therapy,bone marrow minimal residual disease negativity was confirmed with two weeks'blinatumomab infusion.Subsequently,parenchymal infiltration improvement was achieved with additional 14 days'blinatumomab-included targeted therapy.These results suggest that blinatumomab-included therapy is a potential treatment option for central nervous system B-ALL.展开更多
To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]...To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]Allogeneic hematopoietic stem cell transplantation(HSCT)is the golden standard treatment for patients with R/R ALL.Before immunotherapy was introduced into clinical practice,a significant proportion of patients could not undergo HSCT because of serious adverse events from chemotherapy or the inability to achieve an acceptably deep remission.展开更多
基金supported by the National Natural Science Foundation of China(No.82170206 and No.82470213)Project of Disciplines of Excellence(No.20234Z0002)。
文摘Blinatumomab has demonstrated efficacy in B-cell acute lymphoblastic leukemia(B-ALL),achieving a measurable residual disease(MRD)negativity rate of 78%(1).Its addition to consolidation chemotherapy or administration prior to allogeneic hematopoietic stem cell transplantation(allo-HSCT)has been shown to significantly improve overall survival(OS)and relapse-free survival(RFS)in adult B-ALL patients(2,3).
基金supported by grants from the National Natural Science Foundation of China(82170152)Natural Science Foundation of Fujian Province(2023J011313)the Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province(2022ZQNZD 012).
文摘Central nervous system(CNS)relapse in children with acute lymphoblastic leukemia(ALL)remains an obstacle for long-term survival.Though chimeric antigen receptor T-cells(CAR-T)or hematopoietic stem cells transplant(HSCT)therapy was successfully developed,failure occasionally occurs.In this study,a child with TCF3-PBX1 B-ALL who relapsed a second time after CAR-T therapy followed by allo-HSCT was treated with blinatumomab therapy,bone marrow minimal residual disease negativity was confirmed with two weeks'blinatumomab infusion.Subsequently,parenchymal infiltration improvement was achieved with additional 14 days'blinatumomab-included targeted therapy.These results suggest that blinatumomab-included therapy is a potential treatment option for central nervous system B-ALL.
基金supported by grants from the project(No.RDJP2022-71)Peking University People’s Hospital Scientific Research Development Funds and the CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2019-I2M-5-034).
文摘To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]Allogeneic hematopoietic stem cell transplantation(HSCT)is the golden standard treatment for patients with R/R ALL.Before immunotherapy was introduced into clinical practice,a significant proportion of patients could not undergo HSCT because of serious adverse events from chemotherapy or the inability to achieve an acceptably deep remission.
